Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

RetinalGenix Technologies Inc

Company price
3.99 USD 0.00(0%)
Last update at 2026-11-16T21:00:00Z
VOLUME
5
Market Cap
75.37M

Momentum Score

…

RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.99
Low
3.99
High
52 Week Price Range
3.20
Low
4.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.99
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
0.03M
ROCE
105.47%
Diluted EPS TTM
-0.13

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.43M -4.32M -2.09M -3.91M -2.18M
Net income -2.43M -4.32M -2.09M -3.91M -2.18M
Selling general administrative 1.70M 3.24M 1.16M 1.07M 1.50M
Gross profit -0.64M -0.70M -0.40M - -
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M -
Ebit - - - -3.91M -2.18M
Ebitda - - - -3.91M -2.18M
Operating income -2.42M -4.32M -2.09M -3.91M -2.18M
Interest expense 0.00M 0.00M 0.00M 0.01M 0.00M
Net interest income -0.00M -0.00M -0.00M -0.01M -0.00M
Non recurring - - - 2.03M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 2.42M 4.32M 2.09M 3.91M 2.18M
Cost of revenue 0.64M 0.70M 0.40M - -
Total other income expense net - - - -2.03M -0.68M
Net income from continuing ops -2.43M -4.32M -2.09M -3.91M -2.18M
Net income applicable to common shares - - - -3.91M -2.18M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.02M 0.01M 0.00M 0.00M 0.00M
Total liab 2.32M 1.48M 1.41M 1.07M 0.47M
Total stockholder equity -2.30M -1.46M -1.41M -1.07M -0.46M
Other current liab - - - 0.11M 0.14M
Common stock - - - 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -17.86M -15.43M -11.11M -9.02M -5.10M
Cash 0.01M 0.01M 0.00M 0.00M 0.00M
Total current liabilities 2.32M 1.47M 1.41M 1.07M 0.47M
Net debt 0.03M 0.04M 0.05M 0.05M 0.07M
Short term debt - - - 0.05M -
Short long term debt 0.05M 0.05M 0.05M 0.05M 0.07M
Property plant equipment - - - 0.00M -
Total current assets 0.01M 0.01M 0.00M 0.00M 0.00M
Net tangible assets - - - -1.07M -0.46M
Accounts payable 1.08M 0.92M 0.88M 0.91M 0.25M
Common stock total equity - - - 0.00M -
Retained earnings total equity - - - -9.02M -
Non current assets total 0.01M 0.01M 0.00M 0.00M 0.00M
Capital lease obligations 0.01M 0.01M 0.00M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - 0.00M -0.00M -
Change to liabilities - - - 0.23M 0.11M
Total cashflows from investing activities - - - -0.00M -0.00M
Net borrowings - - - 0.11M 0.07M
Total cash from financing activities 0.57M 0.75M 0.45M 0.19M 1.17M
Change to operating activities - - - - 0.05M
Net income -2.43M -4.32M -2.09M -3.91M -2.18M
Change in cash 0.01M 0.01M -0.00M -0.00M 0.00M
Begin period cash flow 0.01M 0.00M 0.00M 0.00M 0.00M
End period cash flow 0.01M 0.01M 0.00M 0.00M 0.00M
Total cash from operating activities -0.56M -0.74M -0.45M -0.20M -1.17M
Issuance of capital stock 0.40M 0.50M 0.00M 0.06M 1.08M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Sale purchase of stock - - - 0.09M -
Change to netincome - - - 3.71M 0.86M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Cash and cash equivalents changes - - - -0.00M -
Change in working capital 0.17M 0.19M 0.41M 0.23M 0.16M
Stock based compensation 1.04M 2.61M 0.66M 0.26M 0.31M
Other non cash items 0.66M 0.78M 0.56M 3.23M 0.55M
Free cash flow -0.56M -0.74M -0.45M -0.20M -1.17M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RTGN
RetinalGenix Technologies Inc
-
-%
3.99 - - - - -42.68
ABT
Abbott Laboratories
-2.82
2.62%
104.63 25.97 17.24 3.57 3.20 16.75
MDT
Medtronic PLC
-
-%
102.32 26.60 15.87 3.35 2.08 14.12
SYK
Stryker Corporation
6.55
2.11%
317.27 29.23 16.86 4.18 4.51 17.16
SEMHF
Siemens Healthineers AG
-
-%
48.26 39.57 21.32 3.01 3.29 16.92

Profile*

RetinalGenix Technologies Inc

RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.

409 Apollo Beach Boulevard, Apollo Beach, FL, United States, 33572

415 578 9583

Name Title Year Born
Dr. Jerry Katzman CEO, Pres & Director 1953
Dr. Jerry Katzman M.D. CEO, President, Interim CFO & Chairman 1953

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…